文献速递前列腺癌

经会阴与经直肠磁共振成像靶向穿刺活检对临床显著前列腺癌检出率是否有影响?系统综述与Meta分析

Is There an Impact of Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Biopsy in Clinically Significant Prostate Cancer Detection Rate? A Systematic Review and Meta-analysis.
PubMed 文献 · Eur Urol Oncol · 2023-08-25

该系统综述与Meta分析比较了磁共振成像(MRI)靶向经会阴(TP)与经直肠(TR)穿刺活检对临床显著前列腺癌(csPCa)的检出率。共纳入11项研究,分别有3522例和5140例患者接受TR和TP MRI靶向活检。总体csPCa检出率两者无统计学显著差异(OR 1.11,95%CI 0.98-1.25;p=0.1),但TP在前壁(OR 2.17)和尖部(OR 1.86)病及PI-RADS 4病(OR 1.57)中检出率更高。

要点

  • 总体人群TR与TP MRI靶向活检的csPCa检出率无统计学显著差异(OR 1.11,95%CI 0.98-1.25)。
  • 前壁病TP较TR检出csPCa的OR为2.17(95%CI 1.46-3.22;p<0.001)。
  • 尖部病TP较TR检出csPCa的OR为1.86(95%CI 1.14-3.03;p=0.01)。

核心结论

  • 当考虑所有活检适应证时,前列腺穿刺活检途径与csPCa检出率之间未发现显著关联。
  • TP途径在前壁和尖部肿瘤中提供检出优势,支持在这些病变位置优先使用TP途径。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed/Medline、Embase和Web of Science数据库至2023年2月,遵循PRISMA指南。
  • 共纳入11项研究,3522例患者接受TR MRI靶向活检,5140例患者接受TP MRI靶向活检。
  • 主要结局为csPCa检出(Gleason分级分组≥2)。
  • 敏感性分析按肿瘤位置、PI-RADS评分和融合类型(认知或软件辅助)进行。

主要发现

  • 总体csPCa检出率TR与TP比较无统计学显著差异(OR 1.11,95%CI 0.98-1.25;p=0.1)。
  • 前壁病:TP较TR检出csPCa的OR为2.17(95%CI 1.46-3.22;p<0.001)。
  • 尖部病:TP较TR检出csPCa的OR为1.86(95%CI 1.14-3.03;p=0.01)。
  • PI-RADS 4病:TP较TR检出csPCa的OR为1.57(95%CI 1.07-2.29;p=0.02)。
  • PI-RADS 3和5病中TR与TP检出csPCa无差异(p>0.05)。

临床怎么用

  • 作者认为,在前壁和尖部肿瘤中TP途径提供检出优势,支持在这些病变位置优先使用TP途径。
  • 作者指出,在总体人群中TP途径未见明确获益。

局限性

  • 主要局限性是大多数纳入研究为回顾性设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: It is unclear whether a magnetic resonance imaging (MRI)-targeted transperineal (TP) biopsy can improve the detection of clinically significant prostate cancer (csPCa). OBJECTIVE: To compare the MRI-targeted TP and transrectal (TR) approaches for csPCa detection. EVIDENCE ACQUISITION: A literature search was conducted using the PubMed/Medline, Embase, and Web of Science databases to identify reports published until February 2023. The Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines were followed to identify eligible studies. The primary outcome was the detection of csPCa (Gleason grade group ≥2). Sensitivity analyses were performed to investigate csPCa detection rates according to tumor location, Prostate Imaging Reporting and Data System (PI-RADS) score, and type of fusion (cognitive or software based). EVIDENCE SYNTHESIS: Eleven studies met our inclusion criteria, and data from 3522 and 5140 patients who underwent, respectively, TR and TP MRI-targeted biopsies were reviewed. No statistically significant difference in the detection of csPCa was observed between the TR and TP approaches (odds ratio [OR] 1.11, 95% confidence interval [CI] 0.98-1.25; p = 0.1). When stratifying patients according to lesion location, the TP approach was associated with higher csPCa detection in case of anterior (OR 2.17, 95% CI 1.46-3.22; p < 0.001) and apical (OR 1.86, 95% CI 1.14-3.03; p = 0.01) lesions. In the subgroup analysis based on PI-RADS score, the TP approach was associated with higher csPCa detection (OR 1.57, 95% CI 1.07-2.29; p = 0.02) in PI-RADS 4 lesions. Conversely, no difference was found in PI-RADS 3 and 5 lesions (p > 0.05). The main limitation was the retrospective design of most included studies. CONCLUSIONS: No significant association was found between the prostate biopsy approach and csPCa detection rate when we considered all biopsy indications. The TP approach provides a detection advantage in anterior and apical tumors, arguing for a preferred use of the TP approach in these lesion locations. PATIENT SUMMARY: The transperineal magnetic resonance imaging-targeted prostate biopsy approach appears to be more effective only for selected lesions. No clear benefit was seen for the transperineal approach in the overall population.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Uleri A, Baboudjian M, Tedde A, et al. Is There an Impact of Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Biopsy in Clinically Significant Prostate Cancer Detection Rate? A Systematic Review and Meta-analysis. Eur Urol Oncol. 2023. PMID: 37634971. doi:10.1016/j.euo.2023.08.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。